GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (MEX:SNY N) » Definitions » 3-Year Share Buyback Ratio

Sanofi (MEX:SNY N) 3-Year Share Buyback Ratio : 0.00% (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sanofi 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Sanofi's current 3-Year Share Buyback Ratio was 0.00%.

The historical rank and industry rank for Sanofi's 3-Year Share Buyback Ratio or its related term are showing as below:

During the past 13 years, Sanofi's highest 3-Year Share Buyback Ratio was 2.10%. The lowest was -24.50%. And the median was 0.10%.

MEX:SNY N's 3-Year Share Buyback Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: -2.2
* Ranked among companies with meaningful 3-Year Share Buyback Ratio only.

Competitive Comparison of Sanofi's 3-Year Share Buyback Ratio

For the Drug Manufacturers - General subindustry, Sanofi's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's 3-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Sanofi's 3-Year Share Buyback Ratio falls into.


;
;

Sanofi 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Sanofi (MEX:SNY N) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Sanofi 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Sanofi's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (MEX:SNY N) » Definitions » 3-Year Share Buyback Ratio
Comparable Companies
XPAR:VIRP LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN GILD PFE BMY TSE:4519 LSE:GSK SHSE:600276 TSE:4568 XTER:BAYN TSE:4578 BIIB
Traded in Other Exchanges
SNYNF:USA SNY:USA 1SAN:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria
Address
46, Avenue de la Great Army, Paris, FRA, 75017
Website
https://www.sanofi.com
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sanofi Headlines

No Headlines